Under the agreement, Gilead can choose to license MGD024, a potential treatment for certain blood cancers.
Further, MGNX will receive $60 million in upfront payment and stands to potentially receive up to $1.7 billion in various milestone payments apart from royalties in the double digits under this collaboration.
Is MGNX Stock a Buy?
The consensus rating for MGNX remains a Strong Buy based on seven Buys and Two Holds. Further, the average analyst price target of $9.29 points to a massive 154.17% potential upside in the stock.
Read full Disclosure